knowledge -WSS

knowledge

author：fashion 2025-10-01 18:45:09 - browse：33

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Let's speed up science by embracing open access publishing

Wikipedia

WSS

Snackable artificial intelligence, expert AI, and the pharma industry

Letters to First Opinion on caregivers, digital health, and more

AstraZeneca chief proposes a novel edit to the drug pricing bill

Listen: Biogen's potential pivot, & Illumina's next chapter

Snackable artificial intelligence, expert AI, and the pharma industry

NIH nominee Bertagnolli will get October confirmation hearing

entertainment

knowledge

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

ASCO: Palliative care found as helpful given virtually as in person

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Medicare details structure of new drug price negotiation program

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Sports medicine is finally prioritizing gender equality

Shifting the focus from loneliness to social health

leisure time

Change Healthcare can notify patients about the breach, HHS says

FDA's Pazdur wants cancer trials to range beyond China alone

Ethical issues complicate the benefits of medical crowdfunding

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Advances in CAR

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

knowledge

hotspot

Wikipedia

Wikipedia